Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Alnylam Pharmaceuticals (ALNY) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Alnylam Pharmaceuticals is one of 1025 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks ...

Alnylam Pharmaceuticals (ALNY) announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to the encouraging news. Please note that Alnylam already markets vutrisiran in the EU under the brand name Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 ...

Alnylam Pharmaceuticals (ALNY) focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of experimental RNAi therapeutics is focused on three strategic therapeutic areas — genetic medicines, cardio-metabolic disease and hepatic infectious disease. Alnylam’s marketed portfolio of drugs comprises Amvuttra (vutrisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Onpattro (patisiran).Let’s delve deeper to discuss four reasons why adding Alnylam stock to your portfolio may prov ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Alnylam Pharmaceuticals (ALNY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Alnylam Pharmaceuticals is one of 1026 individual stocks in the Medical sector. Colle ...

Alnylam Pharmaceuticals NASDAQ: ALNY stock price action has been volatile but is uptrending and has gained 100% in the last two years. The uptrend is driven by increasing expectations for market-disrupting heart treatment and could double the price again. The latest action has the market up more than 65% in the last two months and heading to the $350 to $415 range based on the technicals. Alnylam Pharmaceuticals TodayALNYAlnylam Pharmaceuticals$261.91 +5.70 (+2.22%) 52-Week Range$141.98▼$287.55Price Target$ ...

Core Viewpoint - Alnylam Pharmaceuticals' shares fell 8.5% following the announcement of detailed data from the phase III HELIOS-B study for its investigational RNAi therapeutic, Amvuttra, aimed at treating transthyretin-mediated amyloidosis with cardiomyopathy [1][2]. Group 1: Study Results - The HELIOS-B study met its primary endpoint, showing a statistically significant reduction in all-cause mortality and recurrent cardiovascular events in both the overall and monotherapy populations [1]. - Treatment with vutrisiran resulted in a 30% reduction in mortality in the monotherapy population during the double-blind period, but this reduction was deemed non-significant by management [1]. Group 2: Market Performance - Alnylam's shares have increased by 37.3% year-to-date, significantly outperforming the industry growth of 0.6% [4]. - The company reported sales of $425.4 million for Amvuttra in the first half of 2024, reflecting an 82% year-over-year increase [6]. Group 3: Regulatory and Future Prospects - Alnylam plans to submit a supplemental new drug application for vutrisiran to the FDA using a Priority Review Voucher later in 2024 [5]. - If approved for the new indication, vutrisiran is expected to become the new standard of care for treating ATTR amyloidosis with cardiomyopathy, potentially increasing sales and expanding the patient population [6].

Alnylam Pharmaceuticals (ALNY) , a commercial-stage company, focuses on developing novel therapeutics based on RNAi. The company’s pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas — genetic medicines, cardio-metabolic disease and hepatic infectious disease. Alnylam currently markets four drugs — Amvuttra (vutrisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Onpattro (patisiran).Portfolio of Marketed Drugs Boosts RevenuesAmvuttra, the company’s lead drug, is ...

Alnylam Pharmaceuticals (ALNY) reported second-quarter 2024 adjusted earnings of 56 cents per share against the Zacks Consensus Estimate of a loss of 74 cents. The improvement was primarily driven by the recognition of a payment of approximately $185 million, which was previously deferred, upon modifying Alnylam’s ongoing collaboration with Regeneron (REGN) . The company had incurred a loss of $1.62 per share in the year-ago quarter.The adjusted figure excluded items like stock-based compensation expenses a ...

Financial Data and Key Metrics Changes - In Q2 2024, Alnylam Pharmaceuticals achieved a 34% year-over-year growth in global net product revenues, totaling $410 million, primarily driven by a 37% increase in the TTR business [7][11][25] - The company raised its revenue guidance for the year by 11% at the midpoint, reflecting strong commercial performance [7][30] - Total product revenue for Q2 was $410 million, a 34% increase compared to Q2 2023, with TTR and rare franchises growing by 37% and 25%, respectively [25][26] Business Line Data and Key Metrics Changes - The TTR franchise generated $307 million in global net product revenues, marking a 16% increase from Q1 2024 and a 37% increase from Q2 2023 [11][12] - The rare disease franchise, including GIVLAARI and OXLUMO, reported $13 million in global revenues, with a 25% year-over-year growth [16] - GIVLAARI sales increased by 7% year-over-year, while OXLUMO saw a robust 68% growth [16] Market Data and Key Metrics Changes - In the U.S., combined sales of ONPATTRO and AMVUTTRA increased by 16% from Q1 and 40% year-over-year, driven by strong demand for AMVUTTRA [12] - Internationally, TTR franchise growth also increased by 16% from Q1 and 35% year-over-year, primarily due to AMVUTTRA demand [13] Company Strategy and Development Direction - Alnylam aims to become a top-tier biotech company by developing transformative medicines for rare and prevalent diseases, supported by a high-yielding pipeline [9] - The company is preparing for a potential launch of vutrisiran in ATTR cardiomyopathy, which is expected to significantly enhance its commercial portfolio [8][15] - Alnylam is focused on establishing vutrisiran as the standard of care in ATTR-CM, leveraging its strong relationships with TTR centers and integrated customer-facing teams [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving financial goals, including a compounded annual growth rate of over 40% and sustainable non-GAAP operating income [30] - The positive results from the HELIOS-B study are expected to position vutrisiran as a first-line treatment option, addressing significant unmet medical needs [19][38] Other Important Information - Alnylam plans to host a TTR Investor Day on October 9, 2024, to discuss its leadership in ATTR amyloidosis [9][31] - The company is advancing its pipeline with multiple clinical studies, including a supplemental NDA filing for vutrisiran in late 2024 [20][32] Q&A Session Summary Question: Can you discuss the reimbursement landscape in ATTR cardiomyopathy? - Management highlighted the importance of seamless patient access and minimizing co-pay burdens, leveraging the physician-administered nature of AMVUTTRA [33][35] Question: What feedback have you received from physicians regarding vutrisiran? - Physicians are enthusiastic about the potential of vutrisiran to become the standard of care, especially given the impressive HELIOS-B results [37][39] Question: Will you report KM curves and time to events kinetics at the ESC? - Management confirmed plans to provide detailed results, including baseline characteristics and primary endpoint data, at the upcoming ESC Congress [43][46] Question: Can you provide updates on the ALN-APP program? - The ALN-APP program is progressing well, with ongoing studies in both Alzheimer's disease and cerebral amyloid angiopathy [50][60] Question: How has the nature of discussions with physicians changed since Eplontersen's launch? - Discussions have evolved positively, with increased clarity on product differentiation and the potential for market growth [62][64] Question: What is the strategy for growing the market beyond taking share from tafamidis? - Management emphasized the importance of demonstrating the efficacy of vutrisiran and its unique mechanism of action to access a broader patient population [78][80]

For the quarter ended June 2024, Alnylam Pharmaceuticals (ALNY) reported revenue of $659.83 million, up 107% over the same period last year. EPS came in at $0.56, compared to -$2.21 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $448.44 million, representing a surprise of +47.14%. The company delivered an EPS surprise of +175.68%, with the consensus EPS estimate being -$0.74.While investors closely watch year-over-year changes in headline numbers -- revenue and earn ...